NCT00115219View on ClinicalTrials.gov

Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW)

PHASE4CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 31, 2005

Conditions
Rheumatoid Arthritis
Interventions
DRUG

Etanercept

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00115219 - Evaluating Efficacy and Safety of Etanercept 50 mg Twice Weekly (BIW) in Rheumatoid Arthritis (RA) Subjects Who Are Sub-Optimal Responders to Etanercept 50 mg Once Weekly (QW) | Biotech Hunter | Biotech Hunter